Pimecrolimus
Pimecrolimus is a calcineurin inhibitor that exhibits immunosuppressive, anti-inflammatory, and antinociceptive activities. Pimecrolimus prevents calcineurin from dephosphorylating nuclear factor of activated T cells (NF-AT), inhibiting T cell signaling; this inhibition of T cell signaling also prevents release of pro-inflammatory cytokines. Pimecrolimus is clinically used to treat inflammatory skin diseases such as cutaneous lupus erythematosus and contact dermatitis. This compound also displays some antinociceptive properties and may desensitize transient receptor potential vanilloid receptor 1 (TRPV1) channels in skin sensory neurons.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18954467
| Cas No. |
137071-32-0 |
|---|---|
| Purity |
≥98% |
| Formula |
C43H66ClNO11 |
| Formula Wt. |
810.45 |
| Appearance |
White to off white powder |
Xie ZQ, Lan YZ. Effectiveness of pimecrolimus cream for women patients with sensitive skin and its underlying mechanism. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2012 Aug;34(4):375-8. PMID: 22954121.
Lampropoulos CE, DCruz DP. Topical calcineurin inhibitors in systemic lupus erythematosus. Ther Clin Risk Manag. 2010 Apr 15;6:95-101. PMID: 20421909.
Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005;211(2):174-87. Review. Erratum in: Dermatology. 2005;211(3):292. PMID: 16088174.
Lipozencić J. Pimecrolimus–a safe and effective local immunomodulator in the treatment of inflammatory skin diseases. Acta Dermatovenerol Croat. 2005;13(1):63-9. PMID: 15788149.
Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol. 2003 Sep;17(5):493-503. PMID: 12941081.
